Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults
Launched by NEOGENIS LABORATORIES · Sep 4, 2013
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults between the ages of 18 to 80 years
- • Two blood pressure readings of \>/=135/80 mmHg at rest, thus representing prehypertension
- • Informed consent
- Exclusion Criteria:
- • Existence of any significant internal or cardiovascular disease;
- • Current use of any antihypertensive medication.
- • Inability to give informed consent, or fill out standard questionnaires or inability to follow up clinically.
About Neogenis Laboratories
Neogenis Laboratories is a pioneering clinical trial sponsor dedicated to advancing innovative therapeutic solutions through rigorous research and development. With a strong focus on harnessing the power of biopharmaceuticals, the organization is committed to conducting high-quality clinical trials that adhere to the highest regulatory standards. Neogenis Laboratories collaborates with healthcare professionals and research institutions to accelerate the discovery and evaluation of novel treatments, aiming to improve patient outcomes and address unmet medical needs. Their expertise in clinical trial design and management positions them as a trusted partner in the biopharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beverly Hills, California, United States
Patients applied
Trial Officials
Ernst Schwarz, MD, PhD
Principal Investigator
California Medical Institute, Cedars Sinai Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials